Inhibitor Therapeutics (OTCMKTS:INTI) Posts Earnings Results

Inhibitor Therapeutics (OTCMKTS:INTI) announced its earnings results on Wednesday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.

Inhibitor Therapeutics Trading Up 8.1%

INTI stock traded up $0.01 during trading hours on Friday, hitting $0.10. 7,500 shares of the stock were exchanged, compared to its average volume of 40,522. The firm has a market capitalization of $16.79 million, a P/E ratio of -9.73 and a beta of -0.46. The company has a 50-day simple moving average of $0.08 and a two-hundred day simple moving average of $0.06. Inhibitor Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.12.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc and changed its name to Inhibitor Therapeutics, Inc in August 2019.